Published in Immunotherapy Weekly, September 8th, 2004
"There is currently much interest in generating cytotoxic T lymphocyte (CTL) responses against tumor antigens as a therapy for cancer. In this study mouse fibroblasts (H-2b) were genetically modified to express a costimulatory B7.1 and a mature interleukin (IL)-18, and then loaded with an ovalbumin (OVA) epitope (SIINFEKL, H-2Kb restricted) as a model antigen, and tested for the induction of OVA-specific CTLs in C57BL/6 mice (H-2b). The genetically modified fibroblasts...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly